Sysmex Corp
TSE:6869

Watchlist Manager
Sysmex Corp Logo
Sysmex Corp
TSE:6869
Watchlist
Price: 2 660.5 JPY 0.4% Market Closed
Market Cap: 1.7T JPY

Sysmex Corp
Investor Relations

In the bustling world of healthcare diagnostics, Sysmex Corporation stands as a beacon of innovation and precision. Originating from the vibrant city of Kobe, Japan, the company has mastered the art of transforming complex scientific processes into streamlined solutions. With roots tracing back to the 1960s, Sysmex emerged as a pioneer in the field of hematology, developing technological marvels that analyze blood components with remarkable accuracy. This precision is not merely an academic pursuit; it translates into actionable insights for medical professionals, empowering them to diagnose and monitor conditions ranging from anemia to leukemia with a high degree of reliability. As the lifeblood of medical laboratories worldwide, Sysmex's automated analyzers and testing systems are indispensable tools in pathologies, enabling swift and accurate patient care.

Sysmex's business model is a symphony of product innovation and service excellence. The company thrives by blending advanced technologies with an ever-expanding portfolio of diagnostic instruments and reagents, ensuring that their systems remain both state-of-the-art and user-friendly. Revenue generation for Sysmex is a harmonious balance between instrument sales and the recurring income stream from consumables and after-sales service contracts. This dual approach not only secures initial capital from equipment sales but also ensures sustained engagement with their clients. By investing heavily in research and development, Sysmex continuously pushes the envelope in medical diagnostics, tapping into emerging fields like oncology, hemostasis, and urinalysis. In doing so, it fortifies its position as a global leader, committed to advancing healthcare outcomes through technological innovation and customer-centric practices.

Show more
Loading

Earnings Calls

2024 Q4
Feb 19, 2025
Show Transcript
Previous
Next
Cinemark Reports Strong 2024 Performance with Dividend Reinstatement
2024 Q4
Feb 19, 2025

Cinemark celebrated a robust 2024, entertaining over 200 million guests and achieving record fourth-quarter revenues of $814.3 million, a 28% increase year-over-year. Adjusted EBITDA nearly doubled to $156.9 million, rising the margin by 680 basis points to 19.3%. The company reinstated a quarterly cash dividend of $0.32 per share, reflecting confidence in long-term strategies and financial recovery. For 2025, Cinemark is set to increase capital expenditures to approximately $225 million, focusing on growth and enhancing theater experiences, despite anticipated cost pressures due to rising film rental rates and inflation. Overall, they maintain a positive outlook for revenue growth driven by a strong content slate.

Show Full Analysis

Management

Mr. Iwane Matsui
Senior Managing Executive Officer & Director
No Bio Available
Mr. Chris Cappella
Chief Financial Officer
No Bio Available
Mr. Frank Buescher
Senior Executive Officer
No Bio Available
Mr. Kensuke Iizuka
Senior Executive Officer & Executive VP of Corporate Business Planning Div.
No Bio Available
Mr. Zuo Hui Peng
Executive Officer
No Bio Available
Mr. Takashi Ono
Director & Senior Executive Officer
No Bio Available
Mr. Mitsuhisa Kanagawa
Senior Exec Officer of IVD Business Unit & EVP of Business Strategy Dev
No Bio Available
Reiko Watanabe
Executive Officer & Executive VP of Medical Affairs Div.
No Bio Available
Takaaki Nagai
Executive Officer & Executive VP of System Engineering Div.
No Bio Available
Kinya Uchihashi
Executive Officer & Executive VP of Reagent Production
No Bio Available

Contacts

Address
HYOGO-KEN
Kobe
1-5-1, Wakinohama Kaigandori, Chuo-ku
Contacts
+81782650500.0
www.sysmex.co.jp